Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is a clinical-stage biotechnology company with a pioneering program in detalimogene voraplasmid for Non-Muscle Invasive Bladder Cancer, a disease with high clinical burden. The company's Dually Derivatized Oligochitosan platform offers potential differentiation through low treatment interruption rates and simple handling, potentially appealing to community urology practices. While the latest efficacy data declined significantly, safety remains highly favorable and the company is on track for potential approval decision in 2027 pending durability updates in late 2026.

Bears say

enGene Therapeutics is facing numerous challenges and uncertainties with their gene therapy drug for bladder cancer, including weaker-than-expected durability, a lack of confidence in the mechanism of action, and increased regulatory and commercial risks. These factors have led to a revision of their price target to $4, down from $6, and a downgrade to a Neutral rating. Additionally, the company's financial risk and potential competition from larger companies could also impact their future success. Despite some potential advantages in the market, the company faces significant obstacles in achieving a meaningful market share in the highly competitive NMIBC market.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Jul 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.